Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialisation of dendrimer products for pharmaceutical, life-science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis, and as a condom coating.
|23 Jul 2021||$1.27||$-0.01||-0.78%||342,755||$1.30||$1.30||$1.25|
|22 Jul 2021||$1.28||$-0.01||-0.78%||677,898||$1.29||$1.31||$1.24|
|21 Jul 2021||$1.28||$0.00||0.00%||171,329||$1.29||$1.31||$1.28|
|20 Jul 2021||$1.29||$-0.01||-0.78%||716,829||$1.29||$1.32||$1.25|
|19 Jul 2021||$1.29||$-0.05||-3.72%||608,682||$1.32||$1.32||$1.28|
|16 Jul 2021||$1.35||$-0.02||-1.47%||659,754||$1.36||$1.36||$1.32|
|15 Jul 2021||$1.36||$-0.04||-2.86%||339,918||$1.38||$1.40||$1.35|
|14 Jul 2021||$1.40||$-0.02||-1.41%||339,407||$1.45||$1.45||$1.37|
|13 Jul 2021||$1.42||$0.04||2.91%||674,857||$1.36||$1.44||$1.35|
|12 Jul 2021||$1.38||$0.02||1.48%||688,381||$1.36||$1.38||$1.31|
|09 Jul 2021||$1.36||$0.01||0.75%||546,506||$1.33||$1.37||$1.32|
|08 Jul 2021||$1.34||$-0.04||-2.90%||518,985||$1.38||$1.39||$1.33|
|07 Jul 2021||$1.38||$0.01||0.73%||358,820||$1.37||$1.40||$1.35|
|06 Jul 2021||$1.37||$0.00||0.00%||773,924||$1.39||$1.42||$1.36|
|05 Jul 2021||$1.37||$-0.13||-8.70%||1,573,133||$1.39||$1.46||$1.37|
|02 Jul 2021||$1.50||$-0.03||-1.96%||312,680||$1.53||$1.53||$1.48|
|01 Jul 2021||$1.53||$0.03||2.01%||228,374||$1.52||$1.55||$1.51|
|30 Jun 2021||$1.50||$0.02||1.35%||390,700||$1.48||$1.52||$1.47|
|29 Jun 2021||$1.48||$-0.04||-2.62%||1,009,902||$1.52||$1.52||$1.44|
|28 Jun 2021||$1.53||$-0.05||-3.17%||307,178||$1.55||$1.56||$1.51|
|25 Jun 2021||$1.58||$-0.01||-0.63%||210,521||$1.55||$1.60||$1.55|
|24 Jun 2021||$1.58||$0.08||5.33%||686,649||$1.51||$1.61||$1.50|
|23 Jun 2021||$1.50||$-0.03||-1.96%||878,724||$1.53||$1.54||$1.49|
|24 Nov 2020||Jacinth (Jackie) Fairley||Issued||973||$1,323,580||
Issue of securities. 5,234,242 - Performance Rights
|04 Nov 2020||Peter Turvey||Buy||13||$20,000||
Participation in share purchase plan.
|04 Nov 2020||Robert Thomas||Buy||20||$30,000||
Participation in share purchase plan.
|04 Nov 2020||Jacinth (Jackie) Fairley||Buy||20||$30,000||
Participation in share purchase plan.
|02 Oct 2020||Robert Thomas||Buy||30||$45,550||
|02 Oct 2020||Jacinth (Jackie) Fairley||Cancelled||192||$283,337||
Cancellation of securities. 4,261,021 - Performance Rights
|Ms Zita Peach||Non-Executive Director||Oct 2011||
Ms Peach has more than 25 years of executive commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries. She worked for CSL Limited and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Ms Peach's recent executive position was as the Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Fresenius Kabi, a provider of pharmaceutical products and medical devices to hospitals. Previously, Ms Peach was Vice President, Business Development, for CSL Limited, a position she held for ten years. Ms Peach has international and local expertise in the areas of pharmaceutical/medical device product development, commercialisation of products and technologies, marketing and sales, licensing, M&A and international expansions. She has overseen manufacturing, logistics, regulatory affairs, quality assurance, clinical services, human resources, finance, information technology, public policy, business development, marketing and sales at Managing Director and CEO level. Ms Peach is also a member of the Hudson Institute of Medical Research Board.
|Mr Robert Bain Thomas||Non-Executive DirectorNon-Executive Chairman||Dec 2013||
Mr Thomas has a background in financial services and capital markets and is a non-executive director of Australian listed companies. Formerly he was a Partner of Potter Partners (now UBS) where he was also Head of Research. He is the former Chief Executive Officer(CEO)of County NatWest Securities and then became CEO and then Chairman of Citibank Corporate and Investment Bank in Australia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd, TAL (Australia's life insurance company)and HeartWare International Inc, global manufacturer of left ventricular assist heart pumps. Mr Thomas is Chair of AusBio Ltd and Grahger Retail Securities, and a director of Biotron Limited and O'Connell Street Associates. He has expertise in Mergers & Acquisition(M&A) and capital markets including advising on the floats of Commonwealth Bank of Australia and Qantas, and vast experience in Audit and Risk Management. Mr Thomas is also approved under the NSW prequalification scheme for Audit and Risk Committee Independent Chairs and Members for government/public sector agencies and has previously served as the Chairman of the Audit and Risk Committee of Virgin Australia Limited (for 11 years), HeartWare International Inc, REVA Medical Ltd and the State Library of NSW. He is a member of Risk Committee.
|Mr David McIntyre||Non-Executive Director||Mar 2020||
Mr McIntyre has more than 20 years of executive experience including 18 years in the life science sector, having held executive roles which includes Chief Financial Officer and Chief Operating Officer at HeartWare International, Inc, and Chief Financial Officer & Head of Technical Operations at Braeburn, Inc. Mr McIntyre is currently the Chief Financial Officer of AVITA Therapeutics, Inc. His experience includes seven years as a Partner at Apple Tree Partners, a life science venture capital and growth equity fund, giving him knowledge and contacts, in the US pharma, medical device and biotech markets. During this time, he served as a nonexecutive director of several US life science companies. Prior to entering life sciences, he practiced as a senior attorney at Baker & McKenzie and KPMG specialising in M&A, initial public offerings, and corporate law and also held senior finance roles in both multi-national companies and growth companies. He has experience in the areas of accounting/corporate finance, audit and risk, strategy and risk management. He is a member of Risk Committee.
|Dr Jacinth (Jackie) Kincaid Fairley||Chief Executive OfficerExecutive Director||Jul 2006||
Dr Fairley has more than 30 years of operational experience in the pharmaceutical and biotechnology industries working in senior management roles with companies including CSL Limited (CSL) and Faulding (now Pfizer). In those roles she was part of clinical, regulatory, business development, product development management and general management and at Faulding she was part of Global Product Development, Regulatory Affairs and Business Development for Faulding's Hospital Business which operated in more than 60 countries. She currently sits on the board of the Melbourne Business School and Chairman of the Invest Victoria Advisory Board. She is a past member of the Federal Government's Commonwealth Science Council and Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council.
|Mr Peter R Turvey||Non-Executive DirectorNon-Executive Deputy Chairman||Mar 2012||
Mr Turvey has had more than 30 years of experience in the biotech/pharmaceutical industry having been former Executive Vice President Licensing, Group General Counsel and Company Secretary of global biopharmaceutical company CSL, retiring in 2011. He was also part of the protection and licensing of CSL's intellectual property and for risk management within CSL, which included management of the internal audit function, reporting to the Audit & Risk Management Committee of the Board as well as being the Chairman of the Corporate Risk Management Committee. In his senior executive role at CSL, he was part of CSL's M&A and equity capital raising activities over a 15 year period, including during the time of the float of CSL as a publicly listed company. In addition to his expertise in corporate finance, audit and risk management, Mr Turvey has experience in commercialisation and pharmaceutical product development. Mr Turvey is currently Chairman of ImmVirX Pty Ltd, a NonExecutive Director of Cell Therapies Pty Ltd (a subsidiary of the Peter MacCallum Cancer Centre), and a director of Agriculture Victoria Services Pty Ltd and Phytogene Pty Ltd. He is Chairman of the Risk Committee.
|Mr Nigel Baade||Chief Financial OfficerCompany Secretary||Jan 2009||
|Nigel Baade||Chief Financial OfficerCompany Secretary||
|A Eglezos||VP Business Development||
|J R Paull||VP Development & Regulatory Affairs||
|D J Owen||VP Research||
|Hsbc Custody Nominees (Australia) Limited||121,436,040||32.59%|
|JP Morgan Nominees Australia Pty Limited||49,959,725||13.41%|
|Citicorp Nominees Pty Limited||20,348,290||5.46%|
|BNP Paribas Noms Pty Ltd <Drp>||9,579,940||2.57%|
|National Nominees Limited||8,387,362||2.25%|
|T & N Argyrides Investments P/L <T & N Argyrides Pension A/C>||5,000,000||1.34%|
|Mirrabooka Investments Limited||3,979,571||1.07%|
|Applecross Secretarial Services Pty Ltd <L Gorr Family A/C>||3,361,550||0.90%|
|Ms Jacinth Fairley||3,252,386||0.87%|
|Mr Kingsley Bryan Bartholomew||3,067,072||0.82%|
|Mr Peter Murray Jackson||3,000,000||0.81%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||2,956,271||0.79%|
|HSBC Custody Nominees (Australia) Limited A/C 2||2,487,616||0.67%|
|Dollar Coin Investments Pty Ltd <Cousins Discretionary A/C>||1,990,030||0.53%|
|Merrill Lynch (Australia) Nominees Pty Limited||1,622,100||0.44%|
|Commonwealth Scientific and Industrial Research Organisation||1,448,798||0.39%|
|Mr Mario Thomas Argyrides||1,439,900||0.39%|
|Mr David Michael Hosey + Mrs Andrea Jane Hosey||1,395,684||0.37%|
|Mr Richard Grant Oliver||1,345,267||0.36%|
|Applecross Secretarial Services Pty Ltd||1,118,588||0.30%|